

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 23, 2017**

---

**KALVISTA PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**

(State or other jurisdiction of incorporation)

**001-36830**  
(Commission  
File Number)

**20-0915291**  
(IRS Employer  
Identification No.)

**One Kendall Square  
Building 200, Suite 2203  
Cambridge, MA**  
(Address of principal executive offices)

**02139**  
(Zip Code)

**(857) 999-0075**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On March 23, 2017, KalVista Pharmaceuticals, Inc. (the “Company”) held a special meeting of its stockholders at which the Company’s stockholders voted on the proposals set forth below. The final results regarding each proposal are set forth below.

Proposal No. 1: Approval of the 2017 Equity Incentive Plan:

<u>Votes Cast For</u>	<u>Votes Cast Against</u>	<u>Number of Abstentions</u>	<u>Number of Broker Non-Votes</u>
7,232,865	110,262	943	0

Proposal No. 2: Approval of the 2017 Employee Stock Purchase Plan:

<u>Votes Cast For</u>	<u>Votes Cast Against</u>	<u>Number of Abstentions</u>	<u>Number of Broker Non-Votes</u>
7,303,409	40,245	416	0

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**KALVISTA PHARMACEUTICALS, INC.**

Date: March 27, 2017

By: /s/ Benjamin L. Palleiko  
Benjamin L. Palleiko  
Chief Financial Officer